1623 THW Docket No. TRANSMITTAL LETTER DI-5924 (General - Patent Pending) Zieske et al. Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. E. Peselev 29200 1623 4163 10/628,065 July 25, 2003 Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE DEGRADATION PRODUCTS **COMMISSIONER FOR PATENTS:** Transmitted herewith is: Amendment (9 pgs.); and return receipt postcard. in the above identified application. No additional fee is required. A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. Charge the amount of \boxtimes Credit any overpayment. Charge any additional fee required. Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Robert M. Barrett Reg. No. 30,142 BELL, BOYD & LLOYD LLC P.O. Box 1135

Signature

Chicago, IL 60690-1135

Phone: 312-807-4204

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

04-20-2005 (Date)

Dated: April 20, 2005

Signature of Person Mailing Correspondence

Meather Foster

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zieske et al.

Appl. No.:

10/628,065

Conf. No.:

4163

Filed:

July 25, 2003

Title:

DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE

DEGRADATION PRODUCTS

Art Unit:

1623

Examiner:

E. Peselev

Docket No.: DI-5924 (BBL No. 112713-429)

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Office Action dated January 26, 2005, please amend the aboveidentified patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.